Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 400
- 试验地点
- 1
研究概览
简要总结
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm [IPMN] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.
详细描述
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm [IPMN] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •**Inclusion criteria for patients with PDAC and IPMN:**
- •No history of prior neoplastic diseases;
- •Adequate renal and hepatic function;
- •No hematologic disorders;
- •Age ≥ 18 years;
- •No active infections;
- •Written informed consent.
排除标准
- •Severe pre-existing medical conditions, such as serious illnesses or other medical conditions that could negatively affect study outcomes or pose a high risk to the patient's health;
- •Ongoing therapies that could interfere with the study or alter the results.
研究组 & 干预措施
DIAGNOSTIC
Acquisition of biological material for bio-photonic technology analysis
干预措施: Diagnostic procedures (Diagnostic Test)